Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists

May 1, 2025Bioorganic & medicinal chemistry

Design of strong and stable double-stapled peptides that activate both GLP-1 and GIP receptors

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

DA23-BpyBpy, a newly designed peptide, demonstrates a half-life of 30 minutes in simulated intestinal fluid.

The peptide DA23-BpyBpy exhibits more potent dual agonist activities compared to tirzepatide.
It maintains a balanced effect on glucagon-like peptide-1 and glucose-dependent insulinotropic peptide receptors.
DA23-BpyBpy achieves glucose-lowering effects comparable to semaglutide in a glucose tolerance test in rodents.
Double biaryl stapling combined with α-methylation contributes to the peptide's improved stability for potential oral delivery.

AI simplified

The successful treatment of type 2 diabetes and obesity with tirzepatide highlights the dual agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic peptide receptor (GIPR) as a powerful new generation of anti-diabetic drugs. However, tirzepatide and other GLP-1R/GIPR dual agonists currently in clinical development are linear peptides susceptible to proteolytic cleavage, thus preventing their uses as oral drugs. Previously, we reported the design of the proteolytically stable GLP-1R/GIPR peptide dual agonists via sidechain biaryl stapling. Although the stapled peptides exhibit improved proteolytic stability, they are still not sufficiently stable for oral delivery. Here, we report on the design and synthesis of more stable GLP-1R/GIPR dual agonists through a combined use of double biaryl stapling and α-methylation. One of the double-stapled and α-methylated peptides, DA23-BpyBpy, showed more potent and balanced dual agonist activities than tirzepatide, a half-life of 30 min in simulated intestinal fluid, and equal glucose lowering activity compared to semaglutide in oral glucose tolerance test in rodents. These potent and proteolytically stable double biaryl-stapled analogs should provide valuable lead peptides for developing oral GLP-1R/GIPR dual agonist drugs to treat diabetes and obesity. 10,17 21,28

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief